UK: Can New Diagnostic Tests Help Tackle Antibiotic Resistance?

Last Updated: 2 February 2016
Article by Karen Taylor

Most Read Contributor in UK, August 2017

Antibiotics, first prescribed in the mid-1940s, have for many years been seen as the magic bullet to treat infections. However, as quickly as prescribing commenced, antibiotic resistance emerged. In recent years, serious concerns over antibiotic resistance have grown as inadequate control over their use and lack of understanding or monitoring of resistance has led to the emergence of highly resistant strains of bacteria. These concerns continue to amplify, as evidenced in a recent report by Lord Jim O'Neil, the Treasury Minister and former economist, who calls for more investment in rapid diagnosis of bacterial infections to prevent the misuse of antibiotics.1 This week's blog considers the progress in developing and using rapid diagnostic tests to support the prescribing of antibiotics.

There is considerable evidence of the benefits that antibiotics have brought to global health, with antibiotics estimated to have added, on average, twenty years to everyone's lives. On the other hand, the world now faces the prospect of increasing numbers of infections that have developed a resistance to most currently available antibiotics. Indeed, antimicrobial resistance currently claims at least 700,000 lives a year and, without the development of new medicines, could cause more than 10 million deaths a year by 2050, costing the global economy up to $100 trillion.2

In the UK, a survey commissioned by Public Health England to mark the November 2015 European Antibiotic Awareness day, found that 40 per cent of people are taking antibiotics for coughs or runny noses unnecessarily. The survey also revealed huge gaps in public knowledge on antibiotics, 90 per cent are unaware that drug-resistant bacteria can easily spread from person to person, 40 per cent believed they can treat viral infections and half believe antibiotics weaken your immune system.3

Since the House of Lords Science and Technology enquiry into antibiotic resistance in 2000, there have been numerous national and international enquiries and reports which have identified actions that are urgently needed to tackle the misuse and over-use of antibiotic prescribing. However, the misconception that antibiotics are a cure-all for all ills, has proved a very difficult myth to shift.

In 2013, the Chief Medical Officer for England, Dame Sally Davies, suggested that the risk to public health of the rise in drug-resistant bacteria is just as deadly as climate change and international terrorism.4 The ensuing debate, focussed on the need for more effective control over the use of antibiotics, as well as highlighting the need to find novel ways of funding the development of new antibiotics.

The issue is complex, especially given recent media headlines highlighting the distressing cases of babies and young children misdiagnosed as suffering from viral infections who subsequently died due to an aggressive bacterial infection. Inquests into these cases suggested that antibiotics may well have treated their condition effectively.

For more than a decade, GPs in the UK have been subject to numerous campaigns, incentives and penalties aimed at encouraging them to reduce the prescribing of antibiotics. However, most techniques that diagnose bacterial infections have generally taken days or weeks to show conclusively whether a patient had an infection that could be treated with antibiotics. In the meantime, and often under emotional pressure from patients, antibiotics have been prescribed "just in case". Indeed, various surveys in England have identified that nine out of 10 GPs say they feel pressurised to prescribe antibiotics, and around a quarter of the antibiotic prescriptions issued a year are given unnecessarily for illnesses like colds or ear infections caused by viruses.

But it doesn't have to be like this - one initiative that could help remove such uncertainty is the development of more effective and speedier ways of diagnosing the cause of infections. Not only would doctors benefit from having the right tools to diagnose properly , it would also reassure patients that the doctor actually knows that it is a viral rather than a bacterial infection and be able to agree on the appropriate treatment, curbing unnecessary overuse of certain drugs.  

Rapid diagnostics could also be used in clinical trials, to identify the right study patients, improve clinical care and stewardship, and help get drugs approved for limited populations, all of which would help reinvigorate the antibiotic pipeline and tackle multi-drug resistant infections.

A 2015 consensus report identified the UK as the European leader for research in point-of-care diagnostics. The report suggest that one reason why antibiotic prescribing in the UK remains considerably higher than in many other northern European countries is that needle-prick, point-of-care C-restive protein test (POC CRP)5, is currently massively under-utilised.6 The report suggests that if the test were used more widely it could slash antibiotic prescriptions for respiratory infections in primary care by up to 41.5 per cent, saving the NHS Ł56 million a year on prescription and dispensing costs alone. The report goes on to recommend that Clinical Commissioning Groups develop innovative ways to fund POC CRP testing. Indeed, both the National Institute for Health and Care Excellence and Public Health England have backed the use of POC CRP to help steer the correct course of treatment with respiratory tract infections.7

While rapid diagnostics appear to be the key, they have to be quick, cheap, accurate and accessible to all health settings if they are to be adopted more widely and slash the growth of resistance. For material progress to happen over the next five years, healthcare systems need to leapfrog to using rapid diagnostics, wherever possible, before using an antibiotic.

If the world is to avoid the "apocalyptic scenario" of a post-antibiotic era, which the World Health Organisation says will happen this century unless something drastic is done; everything that can be done needs to be done. Neither the private nor public sector can succeed in the development of new antimicrobials and new technologies that allow quicker diagnosis and facilitate targeted treatment, without the other. Collaborations and partnerships between industry, government and academia will be needed if we are to accelerate development. Given the enormity of the challenge, action will also be needed at a local, national and global level.


1 Rapid Diagnostics. Stopping unnecessary use of antibiotics. Review of Antimicrobial Resistance Chaired by Jim O'Neil. October 2015.

2 Antimicrobial Resistance: Tackling a crisis for the health and wealth of nations. The Review on Antimicrobial Resistance Chaired by Jim O'Neill. December 2014


4 Davies S, Grant J, Catchpole M. The Drugs Don't Work: A Global Threat. Penguin Specials 2013.

5 C Reactive Protein (CRP) is a major acute-phase plasma protein which is produced in response to infection or tissue injury. A recent Cochrane review concluded that a point-of-care biomarker ( CRP) to guide antibiotic treatment of acute respiratory infections (ARIs) in primary care can significantly reduce antibiotic use. See also:

6 Ensuring the Rational Use of Antibiotics in Primary Care using C-Reactive Protein Testing. A Consensus Report. June 2015. See also:

7 NICE. Antimicrobial stewardship: Systems and Processes for Effective Antimicrobial Medicine Use. See also:

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

To print this article, all you need is to be registered on

Click to Login as an existing user or Register so you can print this article.

In association with
Up-coming Events Search
Font Size:
Mondaq on Twitter
Register for Access and our Free Biweekly Alert for
This service is completely free. Access 250,000 archived articles from 100+ countries and get a personalised email twice a week covering developments (and yes, our lawyers like to think you’ve read our Disclaimer).
Email Address
Company Name
Confirm Password
Mondaq Topics -- Select your Interests
 Law Performance
 Law Practice
 Media & IT
 Real Estate
 Wealth Mgt
Asia Pacific
European Union
Latin America
Middle East
United States
Worldwide Updates
Check to state you have read and
agree to our Terms and Conditions

Terms & Conditions and Privacy Statement (the Website) is owned and managed by Mondaq Ltd and as a user you are granted a non-exclusive, revocable license to access the Website under its terms and conditions of use. Your use of the Website constitutes your agreement to the following terms and conditions of use. Mondaq Ltd may terminate your use of the Website if you are in breach of these terms and conditions or if Mondaq Ltd decides to terminate your license of use for whatever reason.

Use of

You may use the Website but are required to register as a user if you wish to read the full text of the content and articles available (the Content). You may not modify, publish, transmit, transfer or sell, reproduce, create derivative works from, distribute, perform, link, display, or in any way exploit any of the Content, in whole or in part, except as expressly permitted in these terms & conditions or with the prior written consent of Mondaq Ltd. You may not use electronic or other means to extract details or information about’s content, users or contributors in order to offer them any services or products which compete directly or indirectly with Mondaq Ltd’s services and products.


Mondaq Ltd and/or its respective suppliers make no representations about the suitability of the information contained in the documents and related graphics published on this server for any purpose. All such documents and related graphics are provided "as is" without warranty of any kind. Mondaq Ltd and/or its respective suppliers hereby disclaim all warranties and conditions with regard to this information, including all implied warranties and conditions of merchantability, fitness for a particular purpose, title and non-infringement. In no event shall Mondaq Ltd and/or its respective suppliers be liable for any special, indirect or consequential damages or any damages whatsoever resulting from loss of use, data or profits, whether in an action of contract, negligence or other tortious action, arising out of or in connection with the use or performance of information available from this server.

The documents and related graphics published on this server could include technical inaccuracies or typographical errors. Changes are periodically added to the information herein. Mondaq Ltd and/or its respective suppliers may make improvements and/or changes in the product(s) and/or the program(s) described herein at any time.


Mondaq Ltd requires you to register and provide information that personally identifies you, including what sort of information you are interested in, for three primary purposes:

  • To allow you to personalize the Mondaq websites you are visiting.
  • To enable features such as password reminder, newsletter alerts, email a colleague, and linking from Mondaq (and its affiliate sites) to your website.
  • To produce demographic feedback for our information providers who provide information free for your use.

Mondaq (and its affiliate sites) do not sell or provide your details to third parties other than information providers. The reason we provide our information providers with this information is so that they can measure the response their articles are receiving and provide you with information about their products and services.

If you do not want us to provide your name and email address you may opt out by clicking here .

If you do not wish to receive any future announcements of products and services offered by Mondaq by clicking here .

Information Collection and Use

We require site users to register with Mondaq (and its affiliate sites) to view the free information on the site. We also collect information from our users at several different points on the websites: this is so that we can customise the sites according to individual usage, provide 'session-aware' functionality, and ensure that content is acquired and developed appropriately. This gives us an overall picture of our user profiles, which in turn shows to our Editorial Contributors the type of person they are reaching by posting articles on Mondaq (and its affiliate sites) – meaning more free content for registered users.

We are only able to provide the material on the Mondaq (and its affiliate sites) site free to site visitors because we can pass on information about the pages that users are viewing and the personal information users provide to us (e.g. email addresses) to reputable contributing firms such as law firms who author those pages. We do not sell or rent information to anyone else other than the authors of those pages, who may change from time to time. Should you wish us not to disclose your details to any of these parties, please tick the box above or tick the box marked "Opt out of Registration Information Disclosure" on the Your Profile page. We and our author organisations may only contact you via email or other means if you allow us to do so. Users can opt out of contact when they register on the site, or send an email to with “no disclosure” in the subject heading

Mondaq News Alerts

In order to receive Mondaq News Alerts, users have to complete a separate registration form. This is a personalised service where users choose regions and topics of interest and we send it only to those users who have requested it. Users can stop receiving these Alerts by going to the Mondaq News Alerts page and deselecting all interest areas. In the same way users can amend their personal preferences to add or remove subject areas.


A cookie is a small text file written to a user’s hard drive that contains an identifying user number. The cookies do not contain any personal information about users. We use the cookie so users do not have to log in every time they use the service and the cookie will automatically expire if you do not visit the Mondaq website (or its affiliate sites) for 12 months. We also use the cookie to personalise a user's experience of the site (for example to show information specific to a user's region). As the Mondaq sites are fully personalised and cookies are essential to its core technology the site will function unpredictably with browsers that do not support cookies - or where cookies are disabled (in these circumstances we advise you to attempt to locate the information you require elsewhere on the web). However if you are concerned about the presence of a Mondaq cookie on your machine you can also choose to expire the cookie immediately (remove it) by selecting the 'Log Off' menu option as the last thing you do when you use the site.

Some of our business partners may use cookies on our site (for example, advertisers). However, we have no access to or control over these cookies and we are not aware of any at present that do so.

Log Files

We use IP addresses to analyse trends, administer the site, track movement, and gather broad demographic information for aggregate use. IP addresses are not linked to personally identifiable information.


This web site contains links to other sites. Please be aware that Mondaq (or its affiliate sites) are not responsible for the privacy practices of such other sites. We encourage our users to be aware when they leave our site and to read the privacy statements of these third party sites. This privacy statement applies solely to information collected by this Web site.

Surveys & Contests

From time-to-time our site requests information from users via surveys or contests. Participation in these surveys or contests is completely voluntary and the user therefore has a choice whether or not to disclose any information requested. Information requested may include contact information (such as name and delivery address), and demographic information (such as postcode, age level). Contact information will be used to notify the winners and award prizes. Survey information will be used for purposes of monitoring or improving the functionality of the site.


If a user elects to use our referral service for informing a friend about our site, we ask them for the friend’s name and email address. Mondaq stores this information and may contact the friend to invite them to register with Mondaq, but they will not be contacted more than once. The friend may contact Mondaq to request the removal of this information from our database.


This website takes every reasonable precaution to protect our users’ information. When users submit sensitive information via the website, your information is protected using firewalls and other security technology. If you have any questions about the security at our website, you can send an email to

Correcting/Updating Personal Information

If a user’s personally identifiable information changes (such as postcode), or if a user no longer desires our service, we will endeavour to provide a way to correct, update or remove that user’s personal data provided to us. This can usually be done at the “Your Profile” page or by sending an email to

Notification of Changes

If we decide to change our Terms & Conditions or Privacy Policy, we will post those changes on our site so our users are always aware of what information we collect, how we use it, and under what circumstances, if any, we disclose it. If at any point we decide to use personally identifiable information in a manner different from that stated at the time it was collected, we will notify users by way of an email. Users will have a choice as to whether or not we use their information in this different manner. We will use information in accordance with the privacy policy under which the information was collected.

How to contact Mondaq

You can contact us with comments or queries at

If for some reason you believe Mondaq Ltd. has not adhered to these principles, please notify us by e-mail at and we will use commercially reasonable efforts to determine and correct the problem promptly.